ScreenerHero
LTGOLatigo Biotherapeutics, Inc.
NAS · US · Healthcare · Biotechnology · latigobio.com
21.25USD-0.68%Mkt Cap: 1.35B $P/E: —

Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provi…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5
ARWR
Arrowhead Pharmaceuticals, Inc.
$12.59BUSD
HeadlineSourceTime
Older
Inside Latigo Biotherapeutics’ IPO: A Non-Opioid Pain Bet Goes Public

A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science and the filings actually show.

24/7 Wall St.
Latigo Biotherapeutics (LTGO) On IPO And Trial Data Looks About Right Valued

Latigo Biotherapeutics (LTGO) recently raised US$345.6 million in its IPO, offering 19,200,000 common shares at US$18 each, following publication in the New England Journal of Medicine of clinical data for its lead non opioid pain candidate LTG-001. See our latest analysis for Latigo Biotherapeutics. Since listing at US$18, Latigo Biotherapeutics’ share price has inched up to US$18.25, with a 1-day and year to date share price return of 1.39%, suggesting only early signs of momentum as...

Simply Wall St.